Literature DB >> 1543812

Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.

S G Chiverton1, C W Howden, D W Burget, R H Hunt.   

Abstract

Although omeprazole has a long duration of action and has usually been given in the morning, there are theoretical advantages in administering antisecretory drugs in the evening as has been shown for the H2-receptor antagonists. The aim of this study was to compare the effects of placebo and 20 mg omeprazole given either in the morning or evening, on gastric acidity, plasma gastrin levels and plasma omeprazole in 6 duodenal ulcer patients. The 24-hour mean pH (+/- S.E.M.) was: placebo 1.7 +/- 0.1; morning doing, 3.9 +/- 1.8 (P less than 0.01); evening dosing, 2.9 +/- 1.1 (N.S.). There was a large inter-individual variability of intragastric acidity in response to omeprazole, which was reflected both in the plasma gastrin and in the area under the plasma omeprazole concentration-time curve. Morning administration of omeprazole is optimal, but variability in the patient response to 20 mg omeprazole is still seen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543812     DOI: 10.1111/j.1365-2036.1992.tb00550.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

Review 1.  The laryngeal and esophageal manifestations of Sjögren's syndrome.

Authors:  Peter C Belafsky; Gregory N Postma
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

2.  Comparative bioavailability study of two oral omeprazole formulations after single and repeated administrations in healthy volunteers.

Authors:  T Duvauchelle; L Millerioux; V Gualano; E Evene; A Alcaide
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer.

Authors:  R J Brummer; R W Stockbrügger
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 4.  Optimising acid inhibition treatment.

Authors:  Fernando Gomollón; Xavier Calvet
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Acid peptic diseases: pharmacological approach to treatment.

Authors:  Alex Mejia; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2009-05       Impact factor: 5.045

6.  Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.

Authors:  R H Holloway; J Dent; F Narielvala; A M Mackinnon
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

7.  Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.

Authors:  Jin-Yan Luo; Chun-Yan Niu; Xue-Qin Wang; You-Ling Zhu; Jun Gong
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 8.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 9.  Progress with proton pump inhibition.

Authors:  N J Bell; R H Hunt
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec

Review 10.  Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review.

Authors:  Agnieszka Wiesner; Małgorzata Zwolińska-Wcisło; Paweł Paśko
Journal:  Int J Environ Res Public Health       Date:  2021-03-29       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.